AtriCure (ATRC) Tops Q2 EPS by 19c; Offers Guidance
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $58.10 -1.73%
EPS Growth %: -300.0%
Financial Fact:
Total operating expenses: 33.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -300.0%
Financial Fact:
Total operating expenses: 33.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.11), $0.19 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $100.9 million versus the consensus estimate of $97.55 million.
GUIDANCE:
AtriCure sees FY2023 EPS of $0.92-$0.94, versus the consensus of ($1.09). AtriCure sees FY2023 revenue of $392-395 million, versus the consensus of $388.4 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Faraday Future unveils nine robot models, prices start at $9,990
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
